TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03386643
Drug: Clobetasol propionate 0.05%
Normalized name: CLOBETASOL PROPIONATE 0.05% OINT
DrugBank: Clobetasol propionate (DB01013)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: The selected patients will receive capsules to be diluted in 15ml of water containing clobetasol propionate 0.05% for mouthwash twice a day for 4 weeks.
Study: NCT04427475
Drug: nafulizumab
Normalized name: Natalizumab
DrugBank: Natalizumab (DB00108)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: nafulizumab
Study: NCT03335007
Drug: Aceclofenac
Normalized name: Aceclofenac
DrugBank: Aceclofenac (DB06736)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aceclofenac 100 mg tablet given one hour before starting the root canal treatment
Study: NCT00653328
Drug: doxil
Normalized name: Doxil
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 50 mg/m2 intravenously every 28 days
Study: NCT04270409
Drug: Isatuximab SAR650984
Normalized name: Isatuximab
DrugBank: Isatuximab (DB14811)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pharmaceutical for: Solution for infusion Route of administration: Intravenous
Study: NCT04270409
Drug: Lenalidomide
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pharmaceutical form: Capsules Route of administration: Oral
Study: NCT04270409
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Pharmaceutical form: Tablets and solution for injection Route of administration: Oral and intravenous
Study: NCT04270409
Drug: Montelukast or equivalent
DrugBank: Montelukast (DB00471)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Auxiliary Medicinal Product (AxMP)/pre-medication; ATC code: R03DC03; Pharmaceutical form: tablet; Route of administration: Oral;
Study: NCT04270409
Drug: Diphenhydramine or equivalent
Normalized name: diphenhydramine / hydrocortisone / pramoxine Medicated Pad or Tape
DrugBank: Diphenhydramine (DB01075)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: AxMP/pre-medication ATC code: R06AA02 Pharmaceutical form: ampule; Route of administration: Intravenous
Study: NCT02141412
Drug: dexmedetomidine 0.25 µg/kg IV
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02141412
Drug: dexmedetomidine 0.5 µg/kg IV
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02141412
Drug: dexmedetomidine 1 µg/kg IV
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00436124
Drug: oseltamivir [Tamiflu]
DrugBank: Oseltamivir acid (DB02600)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02300038
Drug: Lidocaine (Xylocaine)
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: perineuromally administration of 1 ml lidocaine
Study: NCT01468259
Drug: Droxidopa
Normalized name: Droxidopa
DrugBank: Droxidopa (DB06262)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The dose to be used is a single 600 mg dose (2 x 300 mg capsules) of droxidopa.
Study: NCT03499899
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carboplatin was a concentrate for solution for intravenous infusion, came in 100mg/mL and was dosed per area under the curve (AUC) 6 every 21 days. Carboplatin was infused once LAG525 and spartalizumab infusions were completed
Study: NCT04053712
Drug: Glucagon
Normalized name: Glucagon
DrugBank: Glucagon (DB00040)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: GlucaGen(R), Novo Nordisk, DK
Study: NCT03697603
Drug: Brexpiprazole
Normalized name: Brexpiprazole
DrugBank: Brexpiprazole (DB09128)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tablets, Oral, once daily, 14 weeks
Study: NCT01404754
Drug: midomafetamine HCl
Normalized name: Chlorpromazine Hydrochloride
DrugBank: Midomafetamine (DB01454)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 120 mg midomafetamine HCl will be administered in opaque capsules at the outside of one of two experimental sessions, and upon mutual agreement between the investigator and participant, 40 mg may be administered 1.5 to 2.5 hours later.
Study: NCT00527033
Drug: YM178
Normalized name: Mirabegron
DrugBank: Mirabegron (DB08893)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral
Study: NCT01489254
Drug: Glatiramer Acetate (GTR)
Normalized name: Glatiramer
DrugBank: Glatiramer (DB05259)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glatiramer Acetate (GTR) 20 mg daily, for 9 months (Part 1) followed by additional 15 month treatment period (Part 2)
Study: NCT03615833
Drug: Cholecalciferol
Normalized name: Cholecalciferol
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholecalciferol 2.5mg (100 000 UI) , once a month for 3 months
Study: NCT00110669
Drug: Prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisone and dummy preparations for this study will be obtained from Frank's Pharmacy in Ocala, FL and will be supplied as a tablet containing 2.5mg, 5mg, 10mg, 20mg or 50mg Prednisone. Inactive dummy pills of similar look/taste will be supplied to maintain blinding.
Study: NCT00293410
Drug: clofarabine
Normalized name: Clofarabine
DrugBank: Clofarabine (DB00631)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT01489254
Drug: Glatiramer Acetate (Copaxone®)
Normalized name: Glatiramer
DrugBank: Glatiramer (DB05259)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glatiramer Acetate (Copaxone), 20 mg daily, for 9 months followed by additional 15 month GTR 20 mg daily treatment period (Part 2)
Study: NCT01981954
Drug: Solifenacin succinate
Normalized name: Solifenacin Succinate
DrugBank: Solifenacin (DB01591)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral suspension
Study: NCT02958566
Drug: Gabapentin
Normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02976753
Drug: efmoroctocog alfa
Normalized name: EFMOROCTOCOG ALFA
DrugBank: Efmoroctocog alfa (DB11607)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: extended half-life factor VIII product
Study: NCT02976753
Drug: Factor VIII
Normalized name: factor VIII
DrugBank: Antihemophilic factor, human recombinant (DB00025)
Approvals — FDA: no, EMA: no, PMDA: no
Description: conventional factor VIII product
Study: NCT02958566
Drug: Orphenadrine
Normalized name: Orphenadrine
DrugBank: Orphenadrine (DB01173)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02958566
Drug: Lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02958566
Drug: Marcaine
Normalized name: Marcaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02958566
Drug: Ketamine
Normalized name: Ketamine
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02958566
Drug: Methadone
Normalized name: Methadone
DrugBank: Methadone (DB00333)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02958566
Drug: Tramadol
Normalized name: Tramadol
DrugBank: Tramadol (DB00193)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03063086
Drug: salmeterol/fluticasone FDC 50/500 μg b.i.d.
DrugBank: Salmeterol (DB00938)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: C
Study: NCT00489086
Drug: tazarotene
Normalized name: Tazarotene
DrugBank: Tazarotene (DB00799)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tazarotene is a member of the acetylenic class of retinoids.
Study: NCT02958566
Drug: Morphine Sulfate
Normalized name: Morphine Sulfate
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02958566
Drug: Dilaudid
Normalized name: Dilaudid
DrugBank: Hydromorphone (DB00327)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02958566
Drug: Morphine Sulfate
Normalized name: Morphine Sulfate
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PCA
Study: NCT02958566
Drug: Dilaudid
Normalized name: Dilaudid
DrugBank: Hydromorphone (DB00327)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PCA
Study: NCT00111319
Drug: bortezomib
Normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00507819
Drug: Sildenafil
Normalized name: Sildenafil
DrugBank: Sildenafil (DB00203)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: One 20 mg capsule of sildenafil will be taken by mouth three times-a-day.
Study: NCT00004235
Drug: docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00004235
Drug: irinotecan hydrochloride
Normalized name: Irinotecan Hydrochloride
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02972424
Drug: Teriparatide Prefilled Syringe
Normalized name: Teriparatide
DrugBank: Teriparatide (DB06285)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: TPTD 20 mcg
Study: NCT00767728
Drug: Granulated mesalamine
Normalized name: Mesalamine
DrugBank: Mesalazine (DB00244)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.375 g of mesalamine granules were encapsulated in a hard gelatin shell. 1.5 g of eMG (4 capsules) were administered orally QD, in the morning.
Study: NCT00006364
Drug: omacetaxine mepesuccinate
Normalized name: Omacetaxine Mepesuccinate
DrugBank: Omacetaxine mepesuccinate (DB04865)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV or SC
Study: NCT00829140
Drug: Lorcaserin 10mg BID
Normalized name: lorcaserin hydrochloride 10 MG
DrugBank: Lorcaserin (DB04871)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00003259
Drug: vinorelbine tartrate
Normalized name: Vinorelbine Tartrate
DrugBank: Vinorelbine (DB00361)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02426905
Drug: trientine dihydrochloride
Normalized name: trientine dihydrochloride 300 MG Oral Capsule
DrugBank: Triethylenetetramine (DB06824)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: A retrospective review of patients' medical records
Study: NCT00003979
Drug: CHS 828
Normalized name: CHS-828
DrugBank: CHS-828 (DB12980)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03113942
Drug: Pomalidomide 2 MG Oral Capsule [Pomalyst]
Normalized name: pomalidomide 2 MG Oral Capsule [Pomalyst]
DrugBank: Pomalidomide (DB08910)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Pomalidomide is an oral immunomodulatory derivative of thalidomide. Thalidomide and its derivatives are small molecules with broad effects on immune activation, including T-cell activation and responsiveness. Pomalidomide augments T cell responsiveness and proliferation by several mechanisms, many mediated by transcriptional regulation downstream of its primary target, cereblon. Effects include increased production of IL-2 and interferon-γ (IFN-γ), enhanced CD4+ and CD8+ T cell co-stimulation.
Study: NCT02387957
Drug: bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT02387957
Drug: ranibizumab
Normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT02387957
Drug: aflibercept
Normalized name: Aflibercept
DrugBank: Aflibercept (DB08885)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT02308072
Drug: Olaparib
Normalized name: Olaparib
DrugBank: Olaparib (DB09074)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 50 mg, 100 mg, 150 mg or 200 mg taken twice daily (depending on dose under investigation at time of registration) on days 1-3, 1-4 or 1-5 (depending on allocation of treatment schedule) of each week of treatment.
Study: NCT02308072
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 35 mg/m\^2 IV on day 1 of each week of treatment during radiotherapy for a total of 7 weeks (total overall dose 245 mg/m\^2)
Study: NCT02294396
Drug: Mirabegron tablet
Normalized name: Mirabegron
DrugBank: Mirabegron (DB08893)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: orally administered at a dose of 1 tablet once daily after breakfast
Study: NCT02294396
Drug: Solifenacin tablet
Normalized name: solifenacin Oral Tablet
DrugBank: Solifenacin (DB01591)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: orally administered at a dose of 1 tablet once daily after breakfast (could be increased to 2 tablets)
Study: NCT02294396
Drug: Propiverine tablet
DrugBank: Propiverine (DB12278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: orally administered at a dose of 1 tablet once daily after breakfast (could be increased to 1 tablet twice daily after breakfast and after dinner)
Study: NCT00785291
Drug: Ixabepilone
Normalized name: Ixabepilone
DrugBank: Ixabepilone (DB04845)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT02294396
Drug: Imidafenacin tablet
Normalized name: imidafenacin
DrugBank: Imidafenacin (DB09262)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: orally administered at a dose of 1 tablet (0.1 mg tablet) twice daily after breakfast and after dinner (could be increased to 2 tablets twice daily after breakfast and after dinner)
Study: NCT02294396
Drug: Tolterodine capsule
DrugBank: Tolterodine (DB01036)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: orally administered at a dose of 1 capsule once daily after breakfast (could not be increased)
Study: NCT00785291
Drug: Nab-paclitaxel
Normalized name: NAB-PACLITAXEL COMPONENT PACLITAXEL
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given IV
Study: NCT00785291
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given IV
Study: NCT02673398
Drug: Neratinib
Normalized name: NERATINIB
DrugBank: Neratinib (DB11828)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Given PO
Study: NCT02138045
Drug: Liraglutide treatment
Normalized name: Liraglutide
DrugBank: Liraglutide (DB06655)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Treatment continues at highest tolereable dose (minimum 1.2 mg/day). Intervention time 26 weeks at target dose.
Study: NCT02802163
Drug: Panobinostat
Normalized name: Panobinostat
DrugBank: Panobinostat (DB06603)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Induction Phase: Panobinostat (dose escalation beginning at 10 mg) will be administered 3 times a week (TIW) by mouth every other week starting on day 1 of each cycle.~Maintenance Phase: Panobinostat will be administered TIW by mouth every other week starting on day 1 of each cycle. The dose of panobinostat during maintenance phase will be the same dose taken during cyce 8 of induction phase.
Study: NCT02802163
Drug: Carfilzomib
Normalized name: Carfilzomib
DrugBank: Carfilzomib (DB08889)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Induction Phase: Carfilzomib will be administered at 20 mg/m\^2 on Cycle 1 Day 1. Beginning on Cycle 1 Day 2 the carfilzomib dose will be according to the assigned level of 27 mg/m\^2 or 36 mg/m\^2. Carfilzomib will be administered twice weekly IV on Days 1,2, 8,9,15, and 16.
Study: NCT02802163
Drug: Lenalidomide
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Induction Phase: Lenalidomide (25 mg) will be administered once-daily by mouth on Days 1-21, 25.~Maintenance Phase: Lenalidomide (10 mg) will be administered once-daily by mouth on days 1-21.
Study: NCT02802163
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Induction Phase: Dexamethasone (20 mg) will be administered twice weekly by mouth or by IV on Days 1,2, 8, 9, 15, and 16.
Study: NCT02877511
Drug: Sunscreen Lotion (Y65-110)
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Applied liberally to the skin
Study: NCT02259179
Drug: Test naltrexone 8 mg SR/bupropion 90 mg SR combination trilayer tablets (2 tablets)
DrugBank: Naltrexone (DB00704)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04159974
Drug: Durvalumab 50 MG/ML
Normalized name: durvalumab 50 MG/ML
DrugBank: Durvalumab (DB11714)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: IV Infusion
Study: NCT04159974
Drug: Tremelimumab
Normalized name: TREMELIMUMAB
DrugBank: Tremelimumab (DB11771)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV Infusion, Combination with Durvalumab
Study: NCT03107884
Drug: Metformin (Bed Rest)
Normalized name: Rest Simply
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: A clinical oral dose of Metformin will be given to participant daily during bed rest
Study: NCT03107884
Drug: Metformin (2 week run-in only)
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: A clinical oral dose of Metformin will be given to participant daily during a two week run-in period only.
Study: NCT02120833
Drug: Colloidal Oatmeal Cream
Normalized name: Colloidal Oatmeal
DrugBank: Colloidal oatmeal (DB11286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug (including placebo) Apply in a thin layer to the affected skin areas 2 times per day (or as needed) and massage gently into the skin as directed.
Study: NCT00900159
Drug: eszopiclone
Normalized name: Eszopiclone
DrugBank: Eszopiclone (DB00402)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3mg eszopiclone prior to daytime sleep for 3 days (at home) and 1 day (in lab)
Study: NCT02555787
Drug: Tacrolimus
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral
Study: NCT02438826
Drug: Galcanezumab 300 mg
Normalized name: Galcanezumab
DrugBank: Galcanezumab (DB14042)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered SC
Study: NCT01166438
Drug: Botulinum toxin A (Botox A®)
Normalized name: Botulinum toxin type A
DrugBank: Botulinum toxin type A (DB00083)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: A single intradetrusor injection of 100U botulinum toxin A in 10 mL plus 0.1 mL of indigo carmine administered during cytoscopy. Between 100 and 200ml of saline is instilled into the bladder prior to injection to allow adequate visualization of the entire bladder urothelium. The treating physician will inject a total of 10.1 mL of the masked substance into approximately 15 to 20 different detrusor muscle sites under direct visualization using disposable needles. Injections will be spread out to equally cover the posterior bladder wall and dome, but spare the bladder trigone and ureteral orifices.
Study: NCT01166438
Drug: Solifenacin 5mg
DrugBank: Solifenacin (DB01591)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral Solifenacin 5mg once a day for up to 6 months
Study: NCT01166438
Drug: Solifenacin 10mg
DrugBank: Solifenacin (DB01591)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral Solifenacin 10mg once a day for up to 4 months
Study: NCT01166438
Drug: Trospium chloride
Normalized name: Trospium Chloride
DrugBank: Trospium (DB00209)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral Trospium chloride XR 60mg once a day for up to 2 months
Study: NCT03831464
Drug: Metformin Hydrochloride
Normalized name: Metformin Hydrochloride
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: The intervention will consist in IMP treatment during 30 months with half of the patients treated with Metformin Glucophage SR. Tablets of 500mg will be used at a dose of 2x500mg preferably taken during the evening meal.~During the first month of the trial a dose of 1x500mg will be used in order to avoid as much as possible some well-known mainly gastrointestinal side effects of metformin treatment .
Study: NCT00020644
Drug: gemcitabine hydrochloride
Normalized name: Gemcitabine Hydrochloride
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01735201
Drug: AGN-199201 Dose B
Normalized name: AGN-201904
DrugBank: AGN-201904 (DB13135)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AGN-199201 Dose B applied once or twice daily to the face for 28 days.
Study: NCT03688178
Drug: Temozolomide
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Temozolomide is a standard chemotherapy given to all enrolled patients at a targeted dose of 150-200mg/m2/d for 5 days every 4 (+ 2) weeks for up to 12 cycles (patients with unmethylated MGMT gene promoter will receive only cycle 1)
Study: NCT01735201
Drug: AGN-199201 Dose C
Normalized name: Vitamin C
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: AGN-199201 Dose C applied once or twice daily to the face for 28 days.
Study: NCT04333420
Drug: IFX-1 + BSC
Normalized name: IFX-1
DrugBank: Vilobelimab (DB16416)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phase II study part: IFX-1 + BSC
Study: NCT04333420
Drug: BSC
Normalized name: NHPBSC
DrugBank: Autologous Non-Hematopoietic Peripheral Blood Stem Cells (DB15867)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phase II study part: BSC
Study: NCT04333420
Drug: IFX-1 + SOC
Normalized name: IFX-1
DrugBank: Vilobelimab (DB16416)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phase III study part: IFX-1 + SOC
Study: NCT00482677
Drug: temozolomide
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Temozolomide (concurrent with radiation) 75 mg/m2 PO 3 weeks once a day, daily, from the first day to the last day of radiotherapy, but for no longer than 28 days, and then adjuvantly for up to 12 cycles (150 mg/m2 for the first 5 days of each cycle). Adjuvant TMZ may be escalated to 200mg/m2 in C2 onward if appropriate.
Study: NCT02526420
Drug: somavaratan
Normalized name: Somavaratan
DrugBank: Somavaratan (DB12421)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long-acting recombinant human growth hormone therapy administered subcutaneously once monthly
Study: NCT01455532
Drug: Iniparib (SAR240550-BSI-201)
Normalized name: Iniparib
DrugBank: Iniparib (DB13877)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form:Solution for infusion~Route of administration: Intravenous
Study: NCT01455532
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Pharmaceutical form:Solution for infusion~Route of administration: Intravenous
Study: NCT01455532
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Pharmaceutical form:Solution for infusion~Route of administration: Intravenous
Study: NCT01455532
Drug: Placlitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pharmaceutical form:Solution for infusion~Route of administration: Intravenous
Study: NCT00322270
Drug: Alfimeprase
Normalized name: Alfimeprase
DrugBank: Alfimeprase (DB04919)
Approvals — FDA: no, EMA: no, PMDA: no
Description: single-dose of alfimeprase, 10 mg.administered intracatheter to an occluded CVAD
Study: NCT01217476
Drug: Trafermin 0.01% spray
DrugBank: Trafermin (DB06244)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: For ulcers with a maximum diameter (longest axis) of less or equal to 6 cm, the daily dose of trafermin 0.01% spray is 5 puffs (30 microgram) sprayed onto the wound surface. If the maximum diameter (longest axis) of the ulcer is \>6 cm, the ulcer should be sprayed in two parts, i.e. 5 puffs (30 microgram) sprayed onto each half of the wound surface
Study: NCT01497912
Drug: Atorvastatin
Normalized name: Atorvastatin
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atorvastatin 80mg once daily for 8 weeks